Ezetimibe

Overview

Ezetimibe is a synthetic oral small-molecule medicine, not a peptide. It reduces intestinal cholesterol absorption and is used in authorised prescription products for defined lipid-lowering indications. Its presence in an external peptide catalog does not change its chemical class.

Two evidence questions must remain separate. Short-term trials and regulator labels show that ezetimibe lowers LDL cholesterol (LDL-C). Cardiovascular outcome evidence depends on the exact population and comparator: the pivotal IMPROVE-IT trial tested ezetimibe added to simvastatin after acute coronary syndrome, while EWTOPIA 75 studied a selected older Japanese primary-prevention population with a more bias-prone design.

Verified identity

PubChem records ezetimibe as CID 150311, molecular formula C24H21F2NO3, molecular weight 409.4 g/mol, CAS 163222-33-1 and InChIKey OLNTVTPDXPETLC-XPWALMASSA-N. It has a defined organic structure and no amino-acid sequence.

Zetia and Ezetrol are product names, not separate molecules and not shorthand for every authorised indication. Approval attaches to a particular product, label, jurisdiction and patient group.

Mechanism

The current US label identifies Niemann-Pick C1-Like 1 (NPC1L1) as ezetimibe's molecular target. NPC1L1 participates in intestinal uptake of cholesterol and phytosterols. Ezetimibe acts at the small-intestinal brush border, reduces delivery of intestinal cholesterol to the liver, lowers hepatic cholesterol stores and increases LDL-receptor-mediated clearance from blood.

After oral administration, ezetimibe is extensively converted to the pharmacologically active ezetimibe-glucuronide. Mechanistic plausibility and LDL-C lowering do not by themselves prove prevention of myocardial infarction, stroke or death; those claims require outcome trials.

Approved uses and label boundary

The reviewed US label states an initial US approval in 2002 and includes defined uses in primary hyperlipidemia, familial hypercholesterolemia and homozygous familial sitosterolemia, with product- and population-specific combination requirements. The Swedish Medical Products Agency currently lists Ezetimib STADA 10 mg as an approved prescription product, first approved in Sweden on 20 October 2016.

These records verify approved medicines, not unrestricted access or universal indications. They also do not turn a licensed 10 mg tablet into evidence for compounded, counterfeit or research-market products.

Human evidence

LDL-C lowering is a surrogate outcome

In two 12-week placebo-controlled monotherapy trials summarized in the US label, 1,719 adults with primary hyperlipidemia were studied. Pooled label data reported a mean LDL-C change of −18% with ezetimibe versus +1% with placebo. This supports lipid lowering; it is not by itself a cardiovascular-event or survival result.

IMPROVE-IT: combination therapy after acute coronary syndrome

IMPROVE-IT randomized 18,144 patients hospitalized for acute coronary syndrome within the preceding 10 days. Ezetimibe 10 mg plus simvastatin 40 mg was compared with simvastatin 40 mg plus placebo, with a median follow-up of 6 years.

The 7-year Kaplan-Meier rate for the primary composite endpoint was 32.7% versus 34.7% (absolute difference 2.0 percentage points; hazard ratio 0.936, 95% CI 0.89–0.99; P=0.016). Median time-weighted LDL-C was 53.7 versus 69.5 mg/dL. The trial was funded by Merck. The correct conclusion is incremental benefit when ezetimibe was added to statin therapy in this post-acute-coronary-syndrome population—not ezetimibe monotherapy benefit for everyone.

EWTOPIA 75: a narrower monotherapy signal

EWTOPIA 75 enrolled 3,796 Japanese adults aged at least 75 years with elevated LDL-C and no history of coronary artery disease. It used a prospective, randomized, open-label design with blinded endpoint assessment. The primary composite hazard ratio was 0.66 (95% CI 0.50–0.86; P=0.002), while all-cause mortality did not differ.

The authors explicitly cautioned that the magnitude should be interpreted carefully because of the open-label design, premature termination and follow-up issues. This result should not be generalized to younger populations, different baseline risk or mortality benefit.

Pharmacokinetics and product-label dose

The US label reports a plasma half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide, with concentration-time profiles consistent with enterohepatic recycling. It records a product dose of 10 mg orally once daily and timing instructions around bile-acid sequestrants.

Those are label facts, not an invitation to self-treat. Combination requirements, indications, monitoring and suitability depend on the authorised product, liver function, other medicines and clinical context.

Safety and interactions

Important current-label boundaries include:

• myopathy and rhabdomyolysis, especially in reports involving statins or other medicines associated with muscle injury;
• increases in liver enzymes and clinical consideration of withdrawal when persistent ALT or AST elevations reach at least 3× the upper limit of normal;
• increased ezetimibe and cyclosporine exposure during coadministration;
• gallstone-related concern with fibrates and insufficient evidence for fibrates other than fenofibrate;
• reduced ezetimibe exposure with cholestyramine and label-defined separation from bile-acid sequestrants; and
• a recommendation against use in moderate or severe hepatic impairment in the reviewed US label.

Russian-language evidence pass

A 2015 Russian-language open randomized study (PMID 26320293) compared rosuvastatin with atorvastatin plus ezetimibe for 24 weeks in only 31 patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. The combination arm contained 15 people.

Because the trial was small, open, active-comparator and tested a two-drug combination, it cannot isolate ezetimibe's effect or overturn larger labels and outcome trials. Its metabolic findings are retained as a regional evidence signal, not promoted into a universal benefit or harm claim.

Regulation, legality and sport

Ezetimibe is verified here as an approved prescription active substance through the reviewed US label and one currently approved Swedish product entry. That is not a country-by-country legal analysis, and it does not mean every product sold under the name is authorised.

The indexed text of WADA's 2026 Prohibited List did not specifically name ezetimibe, ezetimib or Zetia. This bounded name search is not a clearance statement, does not infer a WADA class and does not replace an athlete's current medication check.

Evidence bottom line

Ezetimibe is a well-characterised, approved non-peptide medicine that lowers LDL-C through intestinal NPC1L1 inhibition. The strongest outcome evidence is specific: incremental cardiovascular benefit when added to simvastatin after acute coronary syndrome. A separate older-Japanese primary-prevention trial provides a monotherapy signal but carries explicit design and follow-up cautions. Nothing in the reviewed evidence supports repositioning ezetimibe as a weight-loss, performance or longevity compound.